Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions... Show more
Mesoblast Limited holds a pioneering position in allogeneic mesenchymal stromal cell (MSC) therapies, with Ryoncil marking the first FDA-approved MSC product for pediatric SR-aGvHD. This achievement validates its proprietary technology platform, which leverages off-the-shelf cells to modulate severe inflammation across multiple disease states. The company's extensive intellectual property portfolio—over 1,000 patents extending to 2044—provides a strong defensive moat in regenerative medicine.
Strategically, Mesoblast benefits from scalable manufacturing processes enabling industrial-scale production, differentiating it from autologous therapies reliant on patient-specific cells. Partnerships with Tasly Pharmaceutical, JCR Pharmaceuticals, and Grünenthal enhance global reach in heart failure, wound healing, and pain management. While the biotech sector faces crowded competition in cell therapies, Mesoblast's focus on inflammatory and cardiovascular indications, coupled with Ryoncil's reimbursement code (J-code) and coverage for over 280 million lives, supports medium-term market penetration and pipeline de-risking.
The near-term horizon features several high-impact events. Mesoblast's inaugural R&D Day on April 8, 2026, will outline Ryoncil growth strategies, pipeline updates in inflammatory pain and cardiovascular disease, and new next-generation technologies, potentially influencing investor sentiment on long-term value.
A BLA submission for Revascor (rexlemestrocel-L) in advanced chronic heart failure patients with LVADs is slated for Q2 2026, supported by data showing reduced bleeding and mortality risks. Positive FDA feedback could accelerate full approval, tapping a sizable unmet need. Site activation for the pivotal adult SR-aGvHD trial follows central IRB approval, leveraging pediatric infrastructure for efficiency. Enrollment completion in the confirmatory CLBP Phase 3 trial is expected in Q2 2026, paving the way for a 2027 BLA.
Analyst sentiment has improved, with Jefferies upgrading to Buy in November 2025 and consensus targets averaging $35 amid revenue growth projections to AUD 180 million in FY2026. Upcoming earnings around May/June 2026 will provide revenue updates against $110–120 million guidance.
The cell and gene therapy market is projected to expand from $10 billion to over $45 billion by 2035, driven by technological adoption and regulatory support for innovative biologics. Mesoblast's allogeneic approach aligns with this tailwind, offering scalability advantages over personalized therapies.
Macro sensitivities include interest rates impacting biotech funding—higher rates could constrain capital access for cash-burning firms like Mesoblast ($130 million runway). Healthcare policy, reimbursement dynamics, and inflation in R&D costs pose challenges, though Ryoncil's J-code mitigates payer hurdles. Geopolitical stability affects supply chains for advanced manufacturing, while FDA efficiency under evolving regulations could expedite approvals. Broader consumer demand in chronic diseases remains resilient, but economic slowdowns might pressure hospital budgets for high-cost therapies.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It analyzes vast datasets to spot developing trends, evaluate possible breakouts or reversals, and provide predictions across a wide range of tradable instruments. The engine includes searchable prediction categories, historical context for pattern recognition, and alert-oriented functionality to notify users of potential shifts. Designed for both novice and experienced investors, it empowers data-driven decisions in dynamic markets. Explore the Trend Prediction Engine today to enhance your trading strategy.
In 2026, Mesoblast's trajectory hinges on Ryoncil ramp-up toward $110–120 million guidance, Revascor BLA progress, and adult SR-aGvHD trial data, potentially tripling the addressable market. Revenue forecasts average AUD 180 million for FY2026, scaling to AUD 332 million in FY2027, with earnings improving from -USD 0.47 to -USD 0.09 per share as margins expand via manufacturing efficiencies.
Long-term drivers include label expansions into inflammatory bowel disease, cost reductions in cell production, and next-gen tech unveilings at R&D Day. Competitive threats from biosimilars and rivals in MSCs loom, but IP strength and partnerships bolster sustainability. Regulatory advancements in cell therapies and capital allocation toward late-stage assets will shape sentiment. Consensus expectations reflect optimism, with price targets signaling upside tied to execution.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
a company, which engages in the development and commercialization of biological products
Industry Biotechnology
A.I.dvisor indicates that over the last year, MESO has been loosely correlated with QTTB. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MESO jumps, then QTTB could also see price increases.
| Ticker / NAME | Correlation To MESO | 1D Price Change % | ||
|---|---|---|---|---|
| MESO | 100% | +2.30% | ||
| QTTB - MESO | 51% Loosely correlated | +2.27% | ||
| TELO - MESO | 43% Loosely correlated | +8.21% | ||
| TNGX - MESO | 33% Poorly correlated | +6.39% | ||
| ZNTL - MESO | 32% Poorly correlated | -7.57% | ||
| TRAW - MESO | 31% Poorly correlated | +3.31% | ||
More | ||||
MESO moved above its 50-day moving average on April 15, 2026 date and that indicates a change from a downward trend to an upward trend. In of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on April 10, 2026. You may want to consider a long position or call options on MESO as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MESO just turned positive on March 25, 2026. Looking at past instances where MESO's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MESO advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for MESO moved below the 200-day moving average on April 08, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MESO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MESO broke above its upper Bollinger Band on April 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MESO entered a downward trend on March 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MESO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.697) is normal, around the industry mean (26.681). P/E Ratio (0.000) is within average values for comparable stocks, (45.953). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.776). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (32.362) is also within normal values, averaging (325.679).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MESO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.